Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Finished Goods (2022 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Finished Goods for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 33.69% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 33.69% increase, with the full-year FY2025 number at $1.1 million, up 33.69% from a year prior.
  • Finished Goods was $1.1 million for Q4 2025 at Ekso Bionics Holdings, up from $943000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.1 million in Q4 2025 to a low of $462000.0 in Q4 2023.
  • A 4-year average of $844166.7 and a median of $847000.0 in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: crashed 46.47% in 2023, then surged 82.47% in 2024.
  • Ekso Bionics Holdings' Finished Goods stood at $863000.0 in 2022, then plummeted by 46.47% to $462000.0 in 2023, then soared by 82.47% to $843000.0 in 2024, then soared by 33.69% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Finished Goods are $1.1 million (Q4 2025), $943000.0 (Q3 2025), and $1.1 million (Q2 2025).